Congruently, therapeutic blockade of αEβ7+ receptors, which is a promising clinical strategy in IBD, leads to greater efflux of cytotoxic/proinflammatory CD8+ and CD4+ T cells from the gut to the draining lymph nodes. This evidence concerns the gene CD4 and inflammatory bowel disease.